{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:01:28Z","timestamp":1780984888671,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of tumors that exhibit a range of biological behaviors, from indolent to aggressive. Identifying prognostic factors for pNETs is essential for risk stratification and personalized treatment planning. Clinicopathological data of stage I to III patients who underwent pancreatic resection and were treated for pNET at an ENETS Center of Excellence from 2009 to 2023 were analyzed retrospectively. 89 pNET patients were included (45 female, 44 male). Proximal pNETs had higher proportions of lymph node metastases (48.4% vs. 17.2%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002) and shorter progression-free survival (PFS) compared to distal tumors (5-year PFS 56.2% vs. 85.0%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003). Subdivision of G2 into G2a (Ki67 3-&lt;10%) and G2b (Ki67 10\u201320%) identified shorter PFS in G2b than in G1 and G2a tumors (5-year PFS G1: 93.6%, G2a: 73.5%, G2b: 34.3%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) while PFS did not differ between G2b and G3 (34.3% vs. 28.6%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.192). Cox regression analyses revealed tumor grading (G2b: HR 8.396 (2.025\u201334.081),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003; G3: HR 17.649 (3.912\u201379.627),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and lymph node metastases (HR 2.657 (1.040\u20136.789),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.041) as risk factors for shorter PFS.Tumor grading and lymph node metastases are independent predictors of postoperative disease progression in pNET patients without distant metastases. Subdividing G2 tumors into G2a and G2b improves prognostic discrimination, with G2b tumors demonstrating outcomes comparable to G3 tumors. These findings support the incorporation of refined grading into treatment and follow-up considerations.\n                  <\/jats:p>","DOI":"10.1007\/s13304-026-02521-0","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:18:44Z","timestamp":1771244324000},"page":"1253-1261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of disease progression in pancreatic neuroendocrine tumors after surgery"],"prefix":"10.1007","volume":"78","author":[{"given":"Eva Maria","family":"Dobrindt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina Maren","family":"Kr\u00f6mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina T.","family":"Mogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Dukaczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Friederieke","family":"M\u00fcller-Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Steinhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli","family":"Fehrenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Malinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Pratschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-1558","authenticated-orcid":false,"given":"Frederike","family":"Butz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"1","key":"2521_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA et al (2022) Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol 33(1):115\u2013154. https:\/\/doi.org\/10.1007\/s12022-022-09708-2","journal-title":"Endocr Pathol"},{"key":"2521_CR2","doi-asserted-by":"publisher","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y et al (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 1;3(10):1335\u20131342 https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589","DOI":"10.1001\/jamaoncol.2017.0589"},{"key":"2521_CR3","doi-asserted-by":"publisher","unstructured":"Stensbol AB, Krogh J, Holmager P, Klose M, Oturai P, Kjaer A et al (2021) Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors. Diagnostics (Basel). 3;11(11) https:\/\/doi.org\/10.3390\/diagnostics11112030","DOI":"10.3390\/diagnostics11112030"},{"issue":"6","key":"2521_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.surg.2012.08.038","volume":"152","author":"LC Lee","year":"2012","unstructured":"Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL et al (2012) Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery 152(6):965\u2013974. https:\/\/doi.org\/10.1016\/j.surg.2012.08.038","journal-title":"Surgery"},{"issue":"12","key":"2521_CR5","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1210\/jc.2013-2604","volume":"98","author":"S Gaujoux","year":"2013","unstructured":"Gaujoux S, Partelli S, Maire F, D\u2019Onofrio M, Larroque B, Tamburrino D et al (2013) Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 98(12):4784\u20134789. https:\/\/doi.org\/10.1210\/jc.2013-2604","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2521_CR6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1245\/s10434-015-4986-1","volume":"23","author":"E Sadot","year":"2016","unstructured":"Sadot E, Reidy-Lagunes DL, Tang LH, Do RK, Gonen M, D\u2019Angelica MI et al (2016) Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: A matched Case-Control study. Ann Surg Oncol 23(4):1361\u20131370. https:\/\/doi.org\/10.1245\/s10434-015-4986-1","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2521_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11605-015-3043-5","volume":"20","author":"IY Zhang","year":"2016","unstructured":"Zhang IY, Zhao J, Fernandez-Del Castillo C, Braun Y, Razmdjou S, Warshaw AL et al (2016) Operative versus nonoperative management of nonfunctioning pancreatic neuroendocrine tumors. J Gastrointest Surg 20(2):277\u2013283. https:\/\/doi.org\/10.1007\/s11605-015-3043-5","journal-title":"J Gastrointest Surg"},{"key":"2521_CR8","doi-asserted-by":"publisher","unstructured":"Sutton TL, Pommier RF, Mayo SC, Gilbert EW, Papavasiliou P, Babicky M et al (2022) Similar outcomes in minimally invasive versus open management of primary pancreatic neuroendocrine tumors: A Regional, Multi-Institutional collaborative analysis. Cancers (Basel) 14(6). https:\/\/doi.org\/10.3390\/cancers14061387","DOI":"10.3390\/cancers14061387"},{"issue":"10","key":"2521_CR9","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1245\/s10434-024-15632-y","volume":"31","author":"OC Eren","year":"2024","unstructured":"Eren OC, Bagci P, Balci S, Ohike N, Saka B, Sokmensuer C et al (2024) Subgrading of G2 pancreatic neuroendocrine tumors as 2A (Ki67 3% to <\u200910%) versus 2B (10% to = 20%) identifies behaviorally distinct subsets in keeping with the evolving management Protocols<\/at. Ann Surg Oncol 31(10):7001\u20137011. https:\/\/doi.org\/10.1245\/s10434-024-15632-y","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2521_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.surg.2012.02.011","volume":"152","author":"NA Hamilton","year":"2012","unstructured":"Hamilton NA, Liu TC, Cavatiao A, Mawad K, Chen L, Strasberg SS et al (2012) Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery 152(1):107\u2013113. https:\/\/doi.org\/10.1016\/j.surg.2012.02.011","journal-title":"Surgery"},{"issue":"1","key":"2521_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00423-024-03563-x","volume":"410","author":"W Izumo","year":"2024","unstructured":"Izumo W, Higuchi R, Furukawa T, Shiihara M, Uemura S, Yazawa T et al (2024) The importance of microvascular invasion in patients with non-functioning pancreatic neuroendocrine neoplasm. Langenbecks Arch Surg 410(1):8. https:\/\/doi.org\/10.1007\/s00423-024-03563-x","journal-title":"Langenbecks Arch Surg"},{"issue":"5","key":"2521_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.dld.2019.01.008","volume":"51","author":"S Partelli","year":"2019","unstructured":"Partelli S, Muffatti F, Rancoita PMV, Andreasi V, Balzano G, Crippa S et al (2019) The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. Dig Liver Dis 51(5):735\u2013740. https:\/\/doi.org\/10.1016\/j.dld.2019.01.008","journal-title":"Dig Liver Dis"},{"issue":"6","key":"2521_CR13","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1245\/s10434-023-13117-y","volume":"30","author":"S Partelli","year":"2023","unstructured":"Partelli S, Andreasi V, Peralta Ferreira M, Palumbo D, Muffatti F, Battistella A et al (2023) Prognostic significance and predictors of nodal recurrence after surgery for Non-Functioning pancreatic neuroendocrine tumors. Ann Surg Oncol 30(6):3466\u20133477. https:\/\/doi.org\/10.1245\/s10434-023-13117-y","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2521_CR14","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1245\/s10434-018-6518-2","volume":"25","author":"CG Genc","year":"2018","unstructured":"Genc CG, Falconi M, Partelli S, Muffatti F, van Eeden S, Doglioni C et al (2018) Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann Surg Oncol 25(8):2467\u20132474. https:\/\/doi.org\/10.1245\/s10434-018-6518-2","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"2521_CR15","doi-asserted-by":"publisher","first-page":"e13343","DOI":"10.1111\/jne.13343","volume":"35","author":"B Kos-Kudla","year":"2023","unstructured":"Kos-Kudla B, Castano JP, Denecke T, Grande E, Kjaer A, Koumarianou A et al (2023) European neuroendocrine tumour society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol 35(12):e13343. https:\/\/doi.org\/10.1111\/jne.13343","journal-title":"J Neuroendocrinol"},{"key":"2521_CR16","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"issue":"7","key":"2521_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/MPA.0000000000001355","volume":"48","author":"N Harimoto","year":"2019","unstructured":"Harimoto N, Hoshino K, Muranushi R, Hagiwara K, Yamanaka T, Ishii N et al (2019) Significance of lymph node metastasis in resectable Well-differentiated pancreatic neuroendocrine tumor. Pancreas 48(7):943\u2013947. https:\/\/doi.org\/10.1097\/MPA.0000000000001355","journal-title":"Pancreas"},{"issue":"7","key":"2521_CR18","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40618-022-01985-2","volume":"46","author":"X Liu","year":"2023","unstructured":"Liu X, Chen B, Chen J, Su Z, Sun S (2023) The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the united States. J Endocrinol Invest 46(7):1373\u20131384. https:\/\/doi.org\/10.1007\/s40618-022-01985-2","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2521_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s12022-021-09687-w","volume":"32","author":"A Aysal","year":"2021","unstructured":"Aysal A, Agalar C, Egeli T, Unek T, Oztop I, Obuz F et al (2021) Reconsideration of clinicopathologic prognostic factors in pancreatic neuroendocrine tumors for better determination of adverse prognosis. Endocr Pathol 32(4):461\u2013472. https:\/\/doi.org\/10.1007\/s12022-021-09687-w","journal-title":"Endocr Pathol"},{"issue":"1","key":"2521_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00423-023-02956-8","volume":"408","author":"L Reinhard","year":"2023","unstructured":"Reinhard L, Mogl MT, Benz F, Dukaczewska A, Butz F, Dobrindt EM et al (2023) Prognostic differences in grading and metastatic lymph node pattern in patients with small bowel neuroendocrine tumors. Langenbecks Arch Surg 408(1):237. https:\/\/doi.org\/10.1007\/s00423-023-02956-8","journal-title":"Langenbecks Arch Surg"},{"issue":"7","key":"2521_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/jso.25896","volume":"121","author":"JR Barrett","year":"2020","unstructured":"Barrett JR, Rendell V, Pokrzywa C, Lopez-Aguiar AG, Cannon J, Poultsides GA et al (2020) Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. J Surg Oncol 121(7):1067\u20131073. https:\/\/doi.org\/10.1002\/jso.25896","journal-title":"J Surg Oncol"},{"issue":"4suppl","key":"2521_CR22","doi-asserted-by":"publisher","first-page":"TPS515","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS515","volume":"40","author":"HP Soares","year":"2022","unstructured":"Soares HP, Guthrie KA, Ahmad SA, Washington MK, Ramnaraign BH, Raj NP et al (2022) Randomized phase II trial of postoperative adjuvant capecitabine and Temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104. J Clin Oncol 40(4suppl):TPS515\u2013TPS515. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.TPS515","journal-title":"J Clin Oncol"},{"issue":"1","key":"2521_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","volume":"49","author":"JR Howe","year":"2020","unstructured":"Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA et al (2020) The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49(1):1\u201333. https:\/\/doi.org\/10.1097\/MPA.0000000000001454","journal-title":"Pancreas"},{"key":"2521_CR24","doi-asserted-by":"publisher","unstructured":"Partelli S, Landoni L, Bartolomei M, Zerbi A, Grana CM, Boggi U et al (2024) Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study. Br J Surg 111(9). https:\/\/doi.org\/10.1093\/bjs\/znae178","DOI":"10.1093\/bjs\/znae178"},{"issue":"8","key":"2521_CR25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/bjs\/znab088","volume":"108","author":"CM Heidsma","year":"2021","unstructured":"Heidsma CM, Engelsman AF, van Dieren S, Stommel MWJ, de Hingh I, Vriens M et al (2021) Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA). Br J Surg 108(8):888\u2013891. https:\/\/doi.org\/10.1093\/bjs\/znab088","journal-title":"Br J Surg"},{"issue":"12","key":"2521_CR26","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/bjs\/znac267","volume":"109","author":"S Partelli","year":"2022","unstructured":"Partelli S, Massironi S, Zerbi A, Niccoli P, Kwon W, Landoni L et al (2022) Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2\u00a0cm: interim analysis of prospective ASPEN trial. Br J Surg 109(12):1186\u20131190. https:\/\/doi.org\/10.1093\/bjs\/znac267","journal-title":"Br J Surg"},{"issue":"1","key":"2521_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.surg.2011.02.022","volume":"150","author":"R Bettini","year":"2011","unstructured":"Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P et al (2011) Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 150(1):75\u201382. https:\/\/doi.org\/10.1016\/j.surg.2011.02.022","journal-title":"Surgery"},{"key":"2521_CR28","doi-asserted-by":"publisher","unstructured":"Moller S, Langer SW, Slott C, Krogh J, Hansen CP, Kjaer A et al (2023) Recurrence-Free survival and Disease-Specific survival in patients with pancreatic neuroendocrine neoplasms: A Single-Center retrospective study of 413 patients. Cancers (Basel) 16(1). https:\/\/doi.org\/10.3390\/cancers16010100","DOI":"10.3390\/cancers16010100"},{"key":"2521_CR29","doi-asserted-by":"publisher","first-page":"107327482098682","DOI":"10.1177\/1073274820986827","volume":"28","author":"M Shi","year":"2021","unstructured":"Shi M, Zhou B (2021) Clinical characteristics and prognostic factors of Early-Onset pancreatic neuroendocrine tumors. Cancer Control 28:1073274820986827. https:\/\/doi.org\/10.1177\/1073274820986827","journal-title":"Cancer Control"},{"issue":"8","key":"2521_CR30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1159\/000511875","volume":"111","author":"W Kwon","year":"2021","unstructured":"Kwon W, Jang JY, Song KB, Hwang DW, Kim SC, Heo JS et al (2021) Risk factors for recurrence in pancreatic neuroendocrine tumor and size as a surrogate in determining the treatment strategy: A Korean nationwide study. Neuroendocrinology 111(8):794\u2013804. https:\/\/doi.org\/10.1159\/000511875","journal-title":"Neuroendocrinology"},{"key":"2521_CR31","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17149-4","author":"S Partelli","year":"2025","unstructured":"Partelli S, Andreasi V, Battistella A, Tamburrino D, Pecorelli N, Crippa S et al (2025) Gender and age as preoperative predictors of early disease progression in patients undergoing surgery for pancreatic neuroendocrine tumors with liver metastases. Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s10434-025-17149-4","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2521_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.surg.2019.03.008","volume":"166","author":"AG Lopez-Aguiar","year":"2019","unstructured":"Lopez-Aguiar AG, Ethun CG, Zaidi MY, Rocha FG, Poultsides GA, Dillhoff M et al (2019) The conundrum of <\u20092-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management. Surgery 166(1):15\u201321. https:\/\/doi.org\/10.1016\/j.surg.2019.03.008","journal-title":"Surgery"},{"issue":"11","key":"2521_CR33","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s00432-020-03303-w","volume":"146","author":"WT Mei","year":"2020","unstructured":"Mei WT, Ding YX, Wang S, Jia YC, Cao F, Li F (2020) Head and body\/tail pancreatic neuroendocrine tumors have different biological characteristics and clinical outcomes. J Cancer Res Clin 146(11):3049\u20133061. https:\/\/doi.org\/10.1007\/s00432-020-03303-w","journal-title":"J Cancer Res Clin"},{"issue":"2","key":"2521_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/Sla.0000000000000348","volume":"259","author":"YM Hashim","year":"2014","unstructured":"Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao DF et al (2014) Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg 259(2):197\u2013203. https:\/\/doi.org\/10.1097\/Sla.0000000000000348","journal-title":"Ann Surg"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02521-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-026-02521-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02521-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:35:54Z","timestamp":1780983354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-026-02521-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2521"],"URL":"https:\/\/doi.org\/10.1007\/s13304-026-02521-0","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin (EA2\/064\/09, 24 August 2009). Patient consent was waived due to the retrospective and non-interventional character of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}